Home Jobs in - India Delhi Mumbai Bangalore Pune Chennai Hyderabad Gurgaon Noida Kolkata
Jobs in India » Pharmaceutical Industry » Recent Developments » Reliance Life to give a shot at generic drug market
Indian Pharma Industry





Reliance Life to give a shot at generic drug market
By 2009, Reliance Life Sciences (RLS) is planning to launch its first generic drug in international markets. In international market, including US and Europe, the company would
compete with global companies such as Mylan or Teva, as well as with the domestic pharma majors like Sun Pharma and Ranbaxy. To have competitive advantage, the company is looking at capital intensive products across all therapeutic segments. However, these drugs are still in the research phase.

Reliance Life Sciences, the newly set up wholly-owned subsidiary of Reliance Pharmaceuticals, will manufacture APIs and generic drugs for the countries across South-East Asia, Africa and CIS as well as for the European and US markets.
The company would market the drug in partnership, as setting up distribution and marketing facilities outside India involves heavy costs. The plan of reliance entering the generic market was announced last year. As of now the company is not going to enter the domestic pharma market. It is looking for opportunities outside India.

According to pharma industry analysts, reliance would be entering a very competitive market, wherein US generic market is under pricing pressure and increased competition and European market are witnessing price cuts. Analysts believe that to be profitable, reliance would need to scale up its business rapidly. It has the financial muscle to complete major acquisition of big pharma player with global manufacturing and distribution capabilities or it can have tie up with some global partner to serve the international market.

Reliance is already into hospital segment through its biopharmaceutical division, and market 5 generic products. It is planning to launch 2 more oncology drugs by the end of 2007 and to export biosimilars to Europe by the end of 2008.